Evidence map›Paper›PMID 33963914›Full record

ArticleInternational journal of colorectal disease2021

Does preoperative neoadjuvant chemotherapy impact short-term surgical outcomes in patients with locally advanced colon cancer?

Ryan Silva, Mohammad Hamidi, Pamela Omesiete, Fawsia Osman, Casey Charlton, Shoujit Banerjee, Timothy Estrada, Valentine Nfonsam

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of colorectal disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 2 pooled it
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Ryan SilvaDepartment of Surgery, University of Arizona Medical Center, Tucson, AZ, USA.
Mohammad HamidiDepartment of Surgery, University of Arizona Medical Center, Tucson, AZ, USA.
Pamela OmesieteDepartment of Surgery, University of Arizona Medical Center, Tucson, AZ, USA.
Fawsia OsmanDepartment of Surgery, University of Arizona Medical Center, Tucson, AZ, USA.
Casey CharltonDepartment of Surgery, University of Arizona Medical Center, Tucson, AZ, USA.
Shoujit BanerjeeDepartment of Surgery, University of Arizona Medical Center, Tucson, AZ, USA.
Timothy EstradaDepartment of Surgery, University of Arizona Medical Center, Tucson, AZ, USA.
Valentine NfonsamDepartment of Surgery, University of Arizona Medical Center, Tucson, AZ, USA. vnfonsam@surgery.arizona.edu.ORCID http://orcid.org/0000-0002-1213-8053
Banner - University Medical Center Tucson · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPreoperative neoadjuvant chemotherapy (NAC) for colon cancer in advanced stages is associated with improved outcomes and tumor regression. The aim of our study was to identify outcomes in patients with colon cancer who received preoperative NAC.

methodsA 4-year analysis of the American College of Surgeons-National Surgical Quality Improvement Program (ACS-NSQIP) was performed. We included patients with locally advanced colon cancer (non-metastatic T3, T4 with or without nodal involvement) who underwent colon cancer resection. Patients were stratified into two groups (NAC and No-NAC). Our outcome measures were anastomotic leaks, hospital length of stay (LOS), 30-day complications, 30-day mortality, and 30-day readmissions. We performed a multi-variable logistic regression analysis.

resultsWe analyzed 90,055 patients of which 7694 (NAC: 7.8 % (n = 599) and No-NAC: 92.2% (n = 7095)) met the inclusion criteria and included in the analysis. Mean age was 67 ± 13 years, 51% were males, and 72% were whites. Patients in the NAC group were more likely to be younger (60 ± 12 years vs. 68 ± 13 years, p < 0.01) and males (62% vs. 50%, p < 0.01) compared to No-NAC. On regression analysis, preoperative NAC was independently associated with higher odds of anastomotic leak (OR 1.35 [1.05-1.97], p = 0.03) and 30-day readmission (OR 1.54 [1.24-2.05], p < 0.01) in reference to No-NAC. However, no association was found between NAC and 30-day complications and 30-day mortality.

conclusionsPreoperative NAC might be associated with adverse outcomes of anastomotic leaks and 30-day readmissions, however does not appear to impact 30-day complications nor 30-day mortality.

Indexed as

Colonic NeoplasmsNeoadjuvant TherapyAgedAged, 80 and overAnastomotic LeakHumansMaleMiddle AgedRetrospective StudiesTreatment OutcomechemotherapyColon cancerLocally advancedNeoadjuvant

Identifiers

PMID33963914
OpenAlexW3158679271

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.